Medications not yet evaluated by P&T are considered NON-FORMULARY . . . . . Always check 2 unique patient identifiers - NAME and DATE OF BIRTH - at every step! . . . . . Please be sure to document all clinical activities daily.
Search results for:

ruxolitinib

ruxolitinib
Drug Name Form Strength Formulary Unrestricted Formulary Restricted Non-Formulary Interchange
Opzelura CREAM, TOPICAL 1.5%      
Jakafi TABLET, ORAL 5 mg, 10 mg, 15 mg, 20 mg, 25 mg      
Comments:

At Huntsville Main/W&C/Madison, orders for this medication should be rejected and reviewed by an oncology clinical specialist or an oncology pool member (see second page of the document "Hormone Therapies and Guidance on Oral Chemotherapy") 

Oral Chemotherapy Drug Pharmacist Education

Oral Chemotherapy TOC Information

JAKAFI is only available through a specialty pharmacy that mails the drug directly to the patient. It is classified as non-formulary, not stocked. Inpatients should use their own supply for continuation of therapy.

Opzelura: Inpatients to use home supply.

Reviewed: March 27, 2012, April 2023 (Opzelura)

Spotlight Ruxolitinib Cream (Opzelura)

 

Last updated: Mar. 5, 2025






This site is intended for the staff of Huntsville Hospital.
While others may view accessible pages, Huntsville Hospital makes no warranty, express or implied,
as to the use of this information outside of Huntsville Hospital.
Please note than many documents are accessible via the provided link
only when connected to the Huntsville Hospital intranet.

Copyright © 2025 Rpharmy, LLC ­ All Rights Reserved